Skip to main content

Table 3 Factors contributing to Psychosocial Summary Score (PsS) in 60 patients with new-onset polyarticular juvenile idiopathic arthritis

From: Health-related quality of life during early aggressive treatment in patients with polyarticular juvenile idiopathic arthritis: results from randomized controlled trial

 UnivariateMixed Model
β (95% CI)/Mean PsS (95% CI)pβ (95% CI)p
Gender (mean) <0.001  
 Female54.66 (53.78 to 55.54)   
 Male51.12 (49.98 to 53.27)   
Time of visit (weeks) 0.036  
 051.00 (49.10 to 52.90)   
 652.02 (50.15 to 53.89)   
 1252.76 (50.89 to 54.63)   
 2453.81 (51.94 to 55.68)   
 3654.48 (52.58 to 56.38)   
 4854.70 (52.82 to 56.58)   
 5454.66 (52.77 to 56.54)   
Age at onset0.134 (-0.92 to 0.36)0.245  
Treatment (mean) 0.113  
 IFX+ MTX53.72 (52.4 to 55.0)0.971a  
 Triple52.4 (51.1 to 53.5)0.139b  
 MTX54.1 (52.8 to 55.3)   
JADAS10-0.251 (-0.378 to -0.125)<0.001-0.038 (-0.24 to 0.16)0.701
Pain-VAS-0.084 (-0.118 to -0.051)<0.0010.001 (-0.055 to 0.58)0.96
Corticosteroid used-0.005 (-0.014 to 0.003)0.193  
Time in remissione0.009 (-0.035 to 0.054)0.679  
CHAQ-5.710 (-7.117 to -4.303)<0.001-5.07 (-7.85 to -2.29)<0.001
CHAQ*JADAS  -0.116 (-0.309 to 0.077)0.237
CHAQ*Pain-VAS  0.047 (-0.011 to 0.105)0.115
  1. For numerical factors, Coefficient beta indicated; for categorical values mean PsS value indicated.
  2. Sidak correction for multiple comparisons used. Factors with p-value <0.05 in univariate analyses were selected for multivariate mixed model. Values shown in Mixed Model column have been adjusted with other variables in the model. IFX+MTX: infliximab plus methotrexate; Triple: methotrexate, hydroxychloroquine, and sulfasalazine; MTX methotrexate monotherapy, JADAS juvenile arthritis disease activity score, VAS visual analoque scale, CHAQ child health assessment questionnaire, PsS Psychosocial summary Score. aIFX+MTX vs MTX; bTriple vs MTX; for IFX+MTX vs Triple p=0.318; dAmount of corticosteroids per body weight (intra-articular or oral) before individual study visit, adjusted for 6 weeks’ time (mg/kg); eCumulative time in remission since onset, *interaction term